MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
MIP Discovery closes £7M Series A financing to drive commercialization in cell and gene therapy space
02/20/24, 9:05 AM
Location
bedfordMoney raised
$9 million
Industry
biotechnology
Round Type
series a
Investors
Calculus Capital, Mercia Ventures
MIP Discovery has closed a £7 million GBP (~$9 million USD) Series A financing round, led by Mercia Ventures. The funding will be used to drive further commercialization of MIP Discovery’s novel synthetic affinity reagents within the cell and gene therapy space, along with supporting recruitment efforts to expand in-house cell and gene therapy expertise.
Company Info
Location
bedford, bedfordshire, united kingdom
Additional Info
MIP Discovery is the leading developer of non-biological affinity reagents, nanoMIPs, for diagnostics and healthcare applications. nanoMIP technology allows for the rapid development of polymer based affinity reagents targeted to small molecules, proteins and viruses, amongst other targets.